Incidence, prevalence, and trend analysis of the use of insulin delivery systems in the United States (2005 to 2011)

References

• International Diabetes Federation (IDF). Diabetes Atlas. Brussels, Belgium: IDF, 2013. Available at: http://www.idf.org/sites/default/files/DA6_Regional_factsheets_0.pdf [Last accessed 28 February 2013]
   Google Scholar
• American Diabetes Association (ADA). Living with Diabetes, Insulin Routines. Alexandria, VA: ADA, 2013. Available at: http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/insulin/insulin-routines.html [Last accessed 28 February 2013]
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9
   PubMed Web of Science ®Google Scholar
• Martin CL, Albers J, Herman WH, et al.; DCCT/EDIC Research Group. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006;29:340-4
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Molife C, Lee LJ, Shi L, et al. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther 2009;11:529-38
   PubMed Web of Science ®Google Scholar
• Ahmann A, Szeinbach SL, Gill J, et al. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes. Diabetes Technol Ther 2014;16:76-83
   PubMed Web of Science ®Google Scholar
• Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004;26:1498-505
   PubMed Web of Science ®Google Scholar
• Eby EL, Boye KS, Lage MJ. Mealtime insulin administration: pens versus vials. Am J Pharm Benefits 2013;5:e159-67
   Google Scholar
• Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract 2011;17:845-52
   PubMed Web of Science ®Google Scholar
• Xie L, Zhou S, Wei W, et al. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. Diabetes Technol Ther 2013;15:230-6
   PubMed Web of Science ®Google Scholar
• Lee LJ, Li Q, Reynolds MW, Engelman W. Trend analyses of insulin delivery systems in the United States. J Diabetes Sci Technol 2011;5:1116-23
   PubMedGoogle Scholar
• Levemir [package insert]. Plainsboro, NJ: Novo Nordisk, 2013
   Google Scholar
• Lantus [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC, 2013
   Google Scholar
• Patient Information for Novolin N. RxList Inc., 2009. Available at: http://www.rxlist.com/novolin-n-innolet-drug/medication-guide.htm [Last accessed 13 October 2014]
   Google Scholar
• Humulin N [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
   Google Scholar
• Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
   Google Scholar
• NovoLog [package insert]. Plainsboro, NJ: Novo Nordisk, 2013
   Google Scholar
• Apidra [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC, 2014
   Google Scholar
• Novolin R [package insert]. Plainsboro, NJ: Novo Nordisk, 2013
   Google Scholar
• Humulin R [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
   Google Scholar
• Humalog Mix75/25 [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
   Google Scholar
• Humalog Mix50/50 [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
   Google Scholar
• NovoLog Mix 70/30 [package insert]. Plainsboro, NJ: Novo Nordisk, 2013
   Google Scholar
• Humulin 70/30 [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
   Google Scholar
• Novolin 70/30 [prescribing information]. Plainsboro, NJ: Novo Nordisk, 2013
   Google Scholar
• Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care 2008;31:430-2
   PubMed Web of Science ®Google Scholar
• Shaghouli AA, Shah BR. The prescription of insulin pen devices versus syringes for older people with diabetes. Diabetes Technol Ther 2009;11:439-42
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• Baser O, Bouchard J, DeLuzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther 2010;27:94-104
   PubMed Web of Science ®Google Scholar
• Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948-62
   PubMed Web of Science ®Google Scholar
• Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1710-25
   Web of Science ®Google Scholar
• Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29(6 Pt 1):1294-305
   Web of Science ®Google Scholar
• Jeitler K, Horvath K, Berghold A, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008;51:941-51
   PubMed Web of Science ®Google Scholar
• Leinung MC, Thompson S, Luo M, et al. Use of insulin pump therapy in patients with type 2 diabetes after failure with multiple daily injections. Endocr Pract 2013;19:9-13
   PubMed Web of Science ®Google Scholar
• Wolff-McDonagh P, Kaufmann J, Foreman S, et al. Using insulin pump therapy in poorly controlled type 2 diabetes. Diabetes Educ 2010;36:657-65
   PubMed Web of Science ®Google Scholar
• Gentry CK, Cross LB, Gross BN, et al. Retrospective analysis and patient satisfaction assessment of insulin pump therapy in patients with type 2 diabetes. South Med J 2011;104:24-8
   PubMed Web of Science ®Google Scholar